Litcius/Paper detail

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Huiyu Li, Zhida Liu, Longchao Liu, Hongyi Zhang, Chuanhui Han, Luc Girard, Hyunsil Park, Anli Zhang, Chunbo Dong, Jianfeng Ye, Austin Rayford, Michael Peyton, Xiaoguang Li, Kimberley Avila, Xuezhi Cao, Shuiqing Hu, Md Maksudul Alam, Esra A. Akbay, Luisa M. Solis, Carmen Behrens, Sharia Hernández-Ruiz, Wei Lü, Ignacio I. Wistuba, John V. Heymach, Michael Chisamore, David Micklem, Hani Gabra, Gro Gausdal, James B. Lorens, Bo Li, Yang‐Xin Fu, John D. Minna, Rolf A. Brekken

2022Cell Reports Medicine94 citationsDOIOpen Access PDF

Abstract

mutant NSCLC.

Topics & Concepts

STK11Cancer researchImmune checkpointCD8KRASMutantCytotoxic T cellBlockadePembrolizumabImmunotherapyCancerImmune systemBiologyMedicineImmunologyIn vitroInternal medicineReceptorGeneColorectal cancerBiochemistryCancer Immunotherapy and BiomarkersPhagocytosis and Immune RegulationPancreatic and Hepatic Oncology Research